Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000

HIV Clinical Trials

Volumn 7, Issue 6, 2006, Pages 271-284

  Mocroft, A ^a   Horban, A ^b   Clumeck, N ^c   Stellbrink, H J ^c,d   d'Arminio Monforte, A ^e   Zilmer, K ^f   Kirk, O ^g   Gatell, J ^h   Phillips, A N ^a   Lundgren, J D ^g   Losso, M ⁱ   Duran, A ⁱ   Vetter, N ^j   Karpov, I ^k   Vassilenko, A ^k   De Wit, S ^c   Poll, B ^c   Colebunders, R ^l   Machala, L ^m   Rozsypal, H ^m   Sedlacek, D ⁿ   Nielsen, J ^g   Benfield, T ^g   Gerstoft, J ^o   Katzenstein, T ^o   Hansen, A B E ^o   Skinhoj P ^o   Pedersen, C ^p   Katlama, C ^q   Viard, J P ^r   Girard, P M ^s   Saint Marc, T ^t   Vanhems, P ^u   Pradier, C ^v   Dabis, F ^w   Dietrich, M ^x   Manegold, C ^x   van Lunzen, L ^y   Staszewski, S ^z   Bickel, M ^z   Goethe, J W ^z   Goebel, F D ^aa   Fatkenheuer G ^ab   Rockstroh, J ^ac   Schmidt, R ^ad   Kosmidis, J ^ae   Gargalianos, P ^ae   Xylomenos, G ^ae   Perdios, J ^ae   Panos, G ^af   Filandras, A ^af   Karabatsaki, E ^af   Banhegyi, D ^ag   Mulcahy, F ^ah   Yust, I ^ai   Turner, D ^ai   Burke, M ^ai   Pollack, S ^aj   Hassoun, G ^aj   Sthoeger, Z ^ak   Maayan, S ^al   Chiesi, A ^am   Esposito, R ^an   Borghi, R ^an   Arici, C ^ao   Pristera, R ^ap   Mazzotta, F ^aq   Gabbuti, A ^aq   Vullo, V ^ar   Lichtnet, M ^ar   Chirianni, A ^as   Montesarchio, E ^as   Antonucci, G ^at   Iacomi, F ^at   Narciso, P ^at   Zaccarelli, M ^at   Lazzarin, A ^au   Finazzi, R ^au   Viksna, L ^av   Chaplinskas, S ^aw   Hemmer, R ^ax   Staub, T ^ax   Reiss, P ^ay   Bruun, J ^az   Maeland, A ^az   Ormaasen, V ^az   Knysz, B ^ba   Gasiorowski, J ^ba   Prokopowicz, D ^bb   Wiercinska Drapalo, A ^bb   Boron Kaczmarska, A ^bc   Pynka, M ^bc   Beniowski, M ^bd   Mularska, E ^bd   Trocha, H ^be   Antunes, F ^bf   Valadas, E ^bf   Mansinho, K ^bg   Matez, F ^bh   more..

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e SAN PAOLO HOSPITAL   (Italy)

^f WEST TALLINN CENTRAL HOSPITAL   (Estonia)

^g HVIDOVRE HOSPITAL   (Denmark)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL RAMOS MEJÍA   (Argentina)

^j Pulmologisches Zentrum   (Austria)

^k BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^l INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^m UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o Rigshospitalet   (Denmark)

^p ODENSE UNIVERSITY HOSPITAL   (Denmark)

^q PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^r HÔPITAL NECKER ENFANTS MALADES   (France)

^s HÔPITAL SAINT ANTOINE   (France)

^t EDOUARD HERRIOT HOSPITAL   (France)

^u UNIVERSITÉ LYON 1   (France)

^v CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^w INSERM   (France)

^x BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^y Medizinische Kernklinik   (Germany)

^z UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^aa Medizinische Poliklinik   (Germany)

^ab UNIVERSITY OF COLOGNE   (Germany)

^ac UNIVERSITY HOSPITAL BONN   (Germany)

^ad HANNOVER MEDICAL SCHOOL   (Germany)

^ae IASO GENERAL HOSPITAL   (Greece)

^af 1st IKA Hospital   (Greece)

^ag Szent Laszlo Hospital   (Hungary)

^ah ST JAMES S HOSPITAL   (Ireland)

^ai TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^aj RAMBAM MEDICAL CENTER   (Israel)

^ak KAPLAN HOSPITAL   (Israel)

^al HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^am ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^an UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^ao OSPEDALI RIUNITI   (Italy)

^ap OSPEDALE CA FONCELLO   (Italy)

^aq SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^ar SAPIENZA UNIVERSITY OF ROME   (Italy)

^as MONALDI HOSPITAL   (Italy)

^at NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^au SAN RAFFAELE HOSPITAL   (Italy)

^av Infectology Centre of Latvia   (Latvia)

^aw Lithuanian AIDS Centre   (Lithuania)

^ax Centre Hospitalier   (Luxembourg)

^ay UNIVERSITY OF AMSTERDAM   (Netherlands)

^az ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^ba WROCLAW MEDICAL UNIVERSITY   (Poland)

^bb MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^bc POMERANIAN MEDICAL UNIVERSITY   (Poland)

^bd Osrodek Diagnostyki i Terapii AIDS   (Poland)

^be MEDICAL UNIVERSITY OF GDANSK   (Poland)

^bf HOSPITAL DE SANTA MARIA   (Portugal)

^bg HOSPITAL EGAS MONIZ   (Portugal)

^bh HOSPITAL CURRY CABRAL   (Portugal)

more..

Author keywords

Combination therapy; Immunologic success; Virologic success

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD;

EID: 33846531821     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0706-271     Document Type: Article

References (37)

1. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://AIDSinfo.nih.gov. Accessed October 10, 2006.
2. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
3. Staszewski S, Moralis-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
4. Robbins GK, de Gruttola V, Sharer RW, et al. Comparison of sequential three drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303.
5. INITIO Trial International Coordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open label randomised trial. Lancet. 2006;368:287-298.
6. Van Leeuwen R, Katlama C, Murphy PL, et al. A randomised trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS. 2003;17:987-999.
7. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2 NN study. Lancet. 2004;363:1253-1263.
8. Podzamczer D, Ferrer E, Consiglio E, et al. A randomised clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV infected naïve patients (the Combine Study). Antiviral Ther. 2002;7:81-90.
9. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001;15:1679-1686.
10. Bucher HC, Bichsel M, Taffe P, et al. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naïve HIV-infected patients: The Swiss HIV Cohort Study. HIV Med. 2002;3:247-253.
11. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002;185:178-187.
12. Yerly S, Perneger TV, Hirschel B, et al. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch Intern Med. 1998; 158:247-252.
13. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 1998;12:1639-1643.
14. Carpenter CCJ, Fischl MA, Hammer SN, et al. Antiretroviral therapy for HIV in 1996: recommendations of an international panel. JAMA. 1996;276:146-154.
15. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
16. Mocroft A, Rockstroh J, Soriano V, et al. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antiviral Ther. 2005;10:779-790.
17. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: results from the EuroSIDA study. AIDS Res Human Retrovirus. 2005;21:743-752.
18. Bartlett JA, Johnson J, Herrera G, et al. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS4001 (CLASS) preliminary 48 week results. In: Program and abstracts of the XIV International AIDS Conference; 2002; Barcelona, Spain. Abstract TuOrB1189.
19. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-2315.
20. Phillips AN, Grabar S, Tassie JM, et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomised trials. AIDS. 1999;13:2075-2082.
21. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
22. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48 week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1 infected patients. J Acquir Immune Defic Syndr. 2004;35:22-32.
23. Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Med. 2003;4:38-47.
24. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001;15:1679-1686.
25. Friedl AC, Ledergerber B, Flepp M, et al. Response to first protease inhibitor and efavirenz containing antiretroviral combination therapy: The Swiss HIV Cohort study. AIDS. 2001;15:1793-1800.
26. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. AIDS. 2002;16:53-61.
27. Bucher HC, Bicshel M, Taffe P, et al. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease-inhibitor naïve HIV infected patients: The Swiss HIV Cohort Study. HIV Med. 2002;3:247-253.
28. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic and clinical response to five different initial protease-inhibitor containing and nevirapine containing regimens. J Acquire Immune Defic Syndr. 2001;27:350-364.
29. Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy. Arch Intern Med. 2006;166:521-528.
30. Bannister WP, Kirk O, Gatell J, et al. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. JAIDS. 2006;42:229-237.
31. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transciptase inhibitor containing and protease-inhibitor containing regimens using observational databases. AIDS. 2001;15:1133-1142.
32. Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chene G. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ. 2004;328:249.
33. van Roon EN, Verzijl JM, Juttmann JR, Lenderinck AW, Blans MJ, Egberts ACG. Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determinants. JAIDS. 1999;20:290-294.
34. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
35. d'Arminio Monfore A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS. 2000;14:499-507.
36. Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 count increases in patients with suppressed viremia. AIDS. 2006;20:1141-1150.
37. Wang D, Zhang W, Bakhai A. Comparison of Bayesian model averaging and stepwise methods for model selection in logistic regression. Stats Med. 2004;23:3451-3467.